Evidence map›Paper›PMID 42208977›Full record

ArticleJournal for immunotherapy of cancer2026

CXCR3 signaling promotes Delta One T cell recruitment and antitumor efficacy in colorectal cancer.

Mariana Carreira, Leandro Barros, Rafael M Cruz, Cristina Ferreira, Carla Costa, Carlos M Ferreira, Sofia Mensurado, Bruno Silva-Santos, Rafael Blanco-Domínguez

Abstract read
In one paragraph

Article in Journal for immunotherapy of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mariana CarreiraGIMM, Lisbon, Portugal.
Leandro BarrosGIMM, Lisbon, Portugal.
Rafael M CruzHospital de Santa Maria, Lisbon, Portugal.
Cristina FerreiraHospital de Santa Maria, Lisbon, Portugal.
Carla CostaHospital de Santa Maria, Lisbon, Portugal.
Carlos M FerreiraHospital de Santa Maria, Lisbon, Portugal.
Sofia MensuradoGIMM, Lisbon, Portugal.
Bruno Silva-SantosUniversidade de Lisboa, Lisboa, Portugal bssantos@medicina.ulisboa.pt rafael.blanco@gimm.pt.ORCID http://orcid.org/0000-0003-4141-9302
Rafael Blanco-DomínguezGIMM, Lisbon, Portugal bssantos@medicina.ulisboa.pt rafael.blanco@gimm.pt.ORCID http://orcid.org/0000-0003-2448-8699

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy has transformed cancer treatment, yet its efficacy in solid tumors, and particularly in colorectal cancer (CRC), remains limited by insufficient infiltration of endogenous or adoptively transferred immune cells. Our group developed Delta One T (DOT) cells, an allogeneic Vδ1-enriched γδ T-cell product with demonstrated efficacy in CRC models, but the critical mechanisms guiding their tumor homing are unclear. Here we show that DOT cells acquire a specific chemokine receptor profile during expansion to support tumor infiltration, characterized by prominent CXCR3 expression. Importantly, CXCR3 ligands (CXCL9-11) are expressed by CRC cell lines and primary tumors, and correlate with Vδ1 T cell infiltration and DOT-cell recruitment. CXCR3 signaling is critical for DOT-cell migration in vitro and in vivo, as pharmacologic blockade reduced tumor homing, whereas enhancing CXCR3 ligand expression increased DOT-cell infiltration and improved tumor control. These findings establish CXCR3 signaling as a key regulator of DOT-cell trafficking and a prime target to boost γδ T cell-based immunotherapies for CRC.

Indexed as

Colorectal NeoplasmsIntraepithelial LymphocytesReceptors, Antigen, T-Cell, gamma-deltaReceptors, CXCR3AnimalsCell Line, TumorCell MovementFemaleHumansMiceSignal TransductionCXCR3 protein, humanReceptors, Antigen, T-Cell, gamma-deltaReceptors, CXCR3Adoptive cell therapy - ACTColorectal CancerT cell

Identifiers

PMID42208977
PMCPMC13223943

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.